2

Single daily inhalation in an easy-to-use inhaler for COPD [1]-[4]
Introducing TRELEGY Ellipta, the only single daily inhalation therapy for COPD that combines ICS, LAMA and LABA. [1]
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. [1]
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting β₂-agonist; LAMA, long acting muscarinic antagonist; OD, once-daily
TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.

© 2017 GlaxoSmithKline Group of Companies. TRELEGY and Ellipta are trademarks of the GSK group of companies.
Materials supplied by the above-country business unit to LOCs, for localisation must be subject to local Medical and/or Regulatory review and approval prior to external distribution